clinical trial · NCT05686551
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease
Hoffmann-La Roche·phase2·active not recruiting·n = 301
Huntington DiseaseTominersenPlacebo
brief summary
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease (HD).
started
Feb 3, 2023
primary completion
May 31, 2026
completion
Apr 1, 2027
last updated
Mar 2, 2026
official title
A Phase II, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen in Individuals With Prodromal and Early Manifest Huntington's Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol